INVESTOR ALERT: Investigation of Salix Pharmaceuticals, Ltd. Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Salix Pharmaceuticals, Ltd. (“Salix” or the “Company”) (NASDAQ:SLXP) concerning possible violations of federal securities laws. The investigation is focused on the Company’s operations and financial performance and prospects. Salix acquires, develops and commercializes prescription drugs and medical devices in the United States to treat various gastrointestinal diseases.

Please contact Lesley Portnoy or Casey Sadler at (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

The investigation is related to the Company’s November 6, 2014, announcement of disappointing financial results for third quarter 2014, including a $88.6 million net loss, or $1.39 per diluted share for the quarter, and a downward revision of the Company’s previous full-year revenue guidance. The Company further announced the resignation of its chief financial officer, and named a senior vice president as interim CFO until a permanent successor is found. Following this news, Salix stock declined nearly 40% in after-hours trading on November 6, 2014.

If you purchased shares of Salix, if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, or Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at (310) 201-9150, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.